Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12730057rdf:typepubmed:Citationlld:pubmed
pubmed-article:12730057lifeskim:mentionsumls-concept:C0225828lld:lifeskim
pubmed-article:12730057lifeskim:mentionsumls-concept:C0064239lld:lifeskim
pubmed-article:12730057lifeskim:mentionsumls-concept:C0205753lld:lifeskim
pubmed-article:12730057lifeskim:mentionsumls-concept:C1955862lld:lifeskim
pubmed-article:12730057lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:12730057pubmed:issue3lld:pubmed
pubmed-article:12730057pubmed:dateCreated2003-8-13lld:pubmed
pubmed-article:12730057pubmed:abstractTextTo examine the receptor specificity and the mechanism of opioid peptide-induced protection, we examined freshly isolated adult rabbit cardiomyocytes subjected to simulated ischemia. Cell death as a function of time was assessed by trypan blue permeability. Dynorphin B (DynB) and Met5-enkephalin (ME) limitation of cell death (expressed as area under the curve) was sensitive to blockade by naltrindole (NTI, a delta-selective antagonist) and 5'-guanidinyl-17-(cyclopropylmethyl)-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan (GNTI dihydrochloride, a kappa-selective antagonist): 85.7 +/- 2.7 and 142.9 +/- 2.7 with DynB and DynB + NTI, respectively (P < 0.001), 94.1 +/- 4.2 and 164.5 +/- 7.3 with DynB and DynB + GNTI, respectively (P < 0.001), 111.9 +/- 7.0 and 192.1 +/- 6.4 with ME and ME + NTI, respectively (P < 0.001), and 120.2 +/- 4.3 and 170.0 +/- 3.3 with ME and ME + GNTI, respectively (P < 0.001). Blockade of ATP-sensitive K+ channels eliminated DynB- and ME-induced protection: 189.6 +/- 5.4 and 139.0 +/- 5.4 for control and ME, respectively (P < 0.001), and 210 +/- 5.9 and 195 +/- 6.1 for 5-HD and ME + 5-HD, respectively (P < 0.001); 136.0 +/- 5.7 and 63.4 +/- 5.4 for control and ME, respectively (P < 0.001), and 144.6 +/- 4.5 and 114.6 +/- 7.7 for HMR-1098 and ME + HMR-1098, respectively (P < 0.01); 189.6 +/- 5.4 and 139.0 +/- 5.4 for control and ME, respectively (P < 0.001), and 210 +/- 5.9 and 195 +/- 6.1 for 5-HD and ME + 5-HD, respectively (P < 0.001); and 136.0 +/- 5.7 and 63.4 +/- 5.4 for control and ME, respectively (P < 0.001), and 144.6 +/- 4.5 and 114.6 +/- 7.7 for HMR-1098 and ME + HMR-1098, respectively (P < 0.01). We conclude that opioid peptide-induced cardioprotection is mediated by delta- and kappa-receptors and involves sarcolemmal and mitochondrial ATP-sensitive K+ channels.lld:pubmed
pubmed-article:12730057pubmed:languageenglld:pubmed
pubmed-article:12730057pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:citationSubsetIMlld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12730057pubmed:statusMEDLINElld:pubmed
pubmed-article:12730057pubmed:monthSeplld:pubmed
pubmed-article:12730057pubmed:issn0363-6135lld:pubmed
pubmed-article:12730057pubmed:authorpubmed-author:LiuLijuanLlld:pubmed
pubmed-article:12730057pubmed:authorpubmed-author:CaoZhipingZlld:pubmed
pubmed-article:12730057pubmed:authorpubmed-author:Van...lld:pubmed
pubmed-article:12730057pubmed:issnTypePrintlld:pubmed
pubmed-article:12730057pubmed:volume285lld:pubmed
pubmed-article:12730057pubmed:ownerNLMlld:pubmed
pubmed-article:12730057pubmed:authorsCompleteYlld:pubmed
pubmed-article:12730057pubmed:paginationH1032-9lld:pubmed
pubmed-article:12730057pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:meshHeadingpubmed-meshheading:12730057...lld:pubmed
pubmed-article:12730057pubmed:year2003lld:pubmed
pubmed-article:12730057pubmed:articleTitleActivation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.lld:pubmed
pubmed-article:12730057pubmed:affiliationResearch and Anesthesiology Services, Veterans Affairs Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA.lld:pubmed
pubmed-article:12730057pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12730057pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12730057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12730057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12730057lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12730057lld:pubmed